Whitepapers

Breaking into Solid Tumors with Armored CAR-T Cells

Solid tumors and the tumor microenvironment (TME) present unique challenges for cell therapies. CAR-T cells have been effective in blood cancers, but the TME poses…

Targeting More with RNA Therapeutics

There is a daunting challenge in the therapeutic space: Many proteins are deemed "undruggable" by traditional small-molecule drugs or antibodies. To date, only 0.05% of…

The Promise, and Challenge, of Oncolytic Viruses for Cancer Therapy

Oncolytic virus (OV) research is emerging as an exciting field of study because of its potential benefits. But as oncolytic viruses have shown promise as…

The Emerging Role of Oncolytic Virus Therapy in Fighting Cancer

The notion of using viruses in cancer therapy is not new. But in the last 15 years, we have begun to understand that the actual…

The Importance of Conducting Due Diligence in an Economic Downturn

Here is a high-level overview of the techniques we use to conduct due diligence and identify potential strategic moves to help with ebbs and flows…

Key Takeaways and Insights from the 41st Annual JP Morgan Healthcare Conference

Kineticos Life Sciences attended the Biotech Showcase, an investor networking conference for biotech and life science innovators to meet with and present to investors and…

Ex Vivo to In Vivo: the Journey of Cell Therapy

Kineticos summarizes the current landscape of in vivo CAR-T cell therapy, to help you stay up to date with the latest trends in CGT.

Autoimmune Disorders: The Next Frontier for CAR-T Therapies

Kineticos summarizes the current landscape of CAR-T cell therapies targeting autoimmune disorders.

Ongoing Challenges and Outlook for Rare Disease Drug Development

There are an estimated 7,000 rare diseases that affect 25 to 30 million people in the United States, more than half of whom are children,…